Bigger may not be better when it comes to hepatocytes
โ Scribed by Stephen C. Strom; Hongbo Cai; Ewa Ellis; Keitaro Mitamura; Toshio Miki
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 65 KB
- Volume
- 12
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.20593
No coin nor oath required. For personal study only.
โฆ Synopsis
Hepatocyte transplantation has gained attention as a potential therapeutic intervention for a number of acute and chronic diseases including fulminant hepatic failure, metabolic liver disease, and cirrhosis. Several decades of research with small animal models has shown that hepatocyte transplants can support liver function and life in animals in acute liver failure. Animal models of metabolic liver disease including tyrosinemia type 1, Crigler-Najjar (Gunn rat), analbuminemia, urea cycle disorders, primary familial intrahepatic cholestasis (PFIC), and Wilson's disease are among the many disorders that have been at least partially corrected by hepatocyte transplantation. [1][2][3][4] A number of centers around the world have conducted hepatocyte transplants in patients in liver failure or even more frequently in patients with metabolic defects in liver function. The results in the clinics are in general agreement with the preclinical data with animal models and support the hypothesis that continued efforts in this field will help bring this cellular therapy to more general use. [5][6][7][8][9][10][11] One of the problems with hepatocyte transplants is the availability of cells for transplantation. The normal sources of hepatocytes are donor livers that cannot be used for whole organ transplantation. This requires that transplant quality cells be isolated from organs that were rejected for whole organ transplant. New sources for hepatocytes will be needed to expand the use of hepatocyte transplants to additional medical centers. Suggested cell sources include immortalized human liver lines, xenotransplants, and stem cell derived sources.
๐ SIMILAR VOLUMES